HC Wainwright & Co. Reiterates Buy on Galectin Therapeutics, Maintains $11 Price Target
Benzinga Newsdesk 4 months ago
Analyst RatingsNewsReiterationPrice Target
HC Wainwright & Co. analyst Matthew Keller reiterates Galectin Therapeutics (NASDAQ:GALT) with a Buy and maintains $11 price target.
HC Wainwright & Co. analyst Matthew Keller reiterates Galectin Therapeutics (NASDAQ:GALT) with a Buy and maintains $11 price target.